Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.

ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.

Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.

Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.

The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.

Nationwide Children's experts urge early screening and family-based lifestyle change as youth-onset T2D progresses faster than adult disease.

Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.

Brittany S. Bruggeman, MD, reviews teplizumab (Tzield), islet autoantibody screening, and automated insulin delivery, and how pediatricians can help families.